Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 1—January 2005
Dispatch

Distribution and Characteristics of Escherichia coli Clonal Group A1

James R. Johnson*†Comments to Author , Andrew C. Murray*†, Michael A. Kuskowski*†, Sören Schubert‡, Marie-Francoise Prère§, Bertrand Picard¶, Raul Colodner#, Raul Raz#**, and TIARAInvestigators
Author affiliations: *VA Medical Center, Minneapolis, Minnesota, USA; †University of Minnesota, Minneapolis, Minnesota, USA; ‡Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, München, Germany; §Centre Hospitalier Universitaire Purpan, Toulouse, France; ¶Hôpital Morvan, Brest, France; #HaEmek Medical Center, Afula, Israel; **Technion School of Medicine, Afula, Israel

Main Article

Figure 2

Virulence traits (top) and antimicrobial resistance phenotypes (bottom) of Escherichia coli clonal group A (CGA) isolates versus non-CGA controls. Percent of isolates positive for each virulence trait (top) or resistance phenotype (bottom) is shown by pink bars to left of midline (for CGA) or blue bars to right of midline (for controls). No isolates were positive for bmaE (M fimbriae), or resistant to amikacin, aztreonam, cefepime, ceftazidime, ertapenem, imipenem-cilistatin, nitrofurantoin, pip

Figure 2. Virulence traits (top) and antimicrobial resistance phenotypes (bottom) of Escherichia coli clonal group A (CGA) isolates versus non-CGA controls. Percent of isolates positive for each virulence trait (top) or resistance phenotype (bottom) is shown by pink bars to left of midline (for CGA) or blue bars to right of midline (for controls). No isolates were positive for bmaE (M fimbriae), or resistant to amikacin, aztreonam, cefepime, ceftazidime, ertapenem, imipenem-cilistatin, nitrofurantoin, piperacillin-tazobactam, or ticarcillin-clavulanate. p value symbols at right of each chart, from Fisher exact test or χ2 test, are for significant differences between CGA and non-CGA. *, p < 0.05; **, p ≤ 0.01; ***, p ≤ 0.001.

Main Article

1Presented at the American Society for Microbiology 103rd General Meeting, May 18–22, 2003, Washington, D.C.

2The TIARA investigators include the following: Sacared Bodison (University of Maryland, College Park, MD), Franklin R. Cockerill, III (Mayo Clinic and Mayo Medical School, Rochester, MN), Clovis Arns da Cunha (Curitiba-PR, Brazil), Peter Echeverria and Sriluck Simasathien (Armed Forces Research Institute of Medical Sciences and Phramonkutkho Army Hospital, Bangkok, Thailand), Wim Gaastra (University of Utrecht, Utrecht, The Netherlands), Lucinda M.C. Hall (St Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK), Marina Klein (McGill University Health Centre, Montreal, Quebec, Canada), Hank A. Lockman (Battelle Memorial Institute, Columbus, OH), Imad Omer and Jane R. Schwebke (University of Alabama, Birmingham, AL), Guillem Prats (Hospital Vall d'Hebron, Barcelona, Spain), Robert M. Rakita (Virginia Mason Medical Center, Seattle, WA), Susan Rossman (Texas Childrens Hospital, Houston, TX), Ronald Schiffman (Southern Arizona VA Medical Center, Tucson, AZ), Ronald Smith (Billings Clinic and Providence Medical Center, Billings, MT), and Patricia L. Winokur (VA Medical Center and University of Iowa, Iowa City, IA).

Page created: April 14, 2011
Page updated: April 14, 2011
Page reviewed: April 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external